Lohn and Wirth published a recent review that mainly focused on TRPM3 involvement in ME/CFS, while also exploring the role of TRPM3 dysfunction in long COVID and the potential benefits of low‐dose naltrexone (LDN) (Lohn and Wirth, 2024). Here, TRPM3 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.